Ernexa Therapeutics Inc. Common Stock (ERNA)
Stock · NASDAQ · Health Care
$2.09as of 10/16/2026
Price chart
Active signals
ERNA Signal Track Record
How signals performed across all stocks →What ERNA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 25 | -14.8% | 28% | October 1, 2026 |
| Bollinger Band Breakout | 14 | -10.5% | 43% | May 6, 2026 |
| Volume Spike | 6 | +2.9% | 50% | October 7, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +3.3% | 57% | August 29, 2024 |
| Any 20-session window (baseline) | -11.3% | 29% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ERNA
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rhe…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 5
- Website
- www.ernexatx.com/
Fundamentals
- 1-day range
- $2.05$2.23
- Market cap
- $5.09M
- P/E (trailing)
- —
- P/E (forward)
- -0.23
- EPS (trailing)
- $-25.77
- Dividend yield
- —
- Beta
- 2.68
- Avg. volume
- 68.4K
How Ernexa Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 12, 2025 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Ernexa Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ERNAErnexa Therapeutics Inc. Common Stock$2.09▼ 3.69%Market cap $5.09MP/E —$2.01$71.5
- GOVXGeoVax Labs Inc. Common Stock$0.238▼ 7.75%Market cap $5.31MP/E —$0.24$15.75
- BGMSBio Green Med Solution Inc. Common Stock$0.91▲ 9.64%Market cap $5.35MP/E —$0.5664$6.11
- PPCBPropanc Biopharma Inc. Common Stock$0.342▲ 0.15%Market cap $4.76MP/E —$0.365$47.5
- CURXCuranex Pharmaceuticals Inc Common Stock$4.62▼ 4.35%Market cap $5.53MP/E —$3.58$16.94
- JAGXJaguar Health Inc. Common Stock$3.53▼ 23.20%Market cap $4.61MP/E —$2.35$1,268
- RNAZTransCode Therapeutics Inc. Common Stock$1.7▼ 5.56%Market cap $4.52MP/E —$1.52$15.94
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ERNA Ernexa Therapeutics Inc. Common Stock | $5.09M | — | $2.09 | ▼ 3.69% | $2.01$71.5 |
| GOVX GeoVax Labs Inc. Common Stock | $5.31M | — | $0.238 | ▼ 7.75% | $0.24$15.75 |
| BGMS Bio Green Med Solution Inc. Common Stock | $5.35M | — | $0.91 | ▲ 9.64% | $0.5664$6.11 |
| PPCB Propanc Biopharma Inc. Common Stock | $4.76M | — | $0.342 | ▲ 0.15% | $0.365$47.5 |
| CURX Curanex Pharmaceuticals Inc Common Stock | $5.53M | — | $4.62 | ▼ 4.35% | $3.58$16.94 |
| JAGX Jaguar Health Inc. Common Stock | $4.61M | — | $3.53 | ▼ 23.20% | $2.35$1,268 |
| RNAZ TransCode Therapeutics Inc. Common Stock | $4.52M | — | $1.7 | ▼ 5.56% | $1.52$15.94 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Ernexa Therapeutic To Present New Preclinical Data From Its ERNA-101 Lead Oncology Program At The Next-Generation Cancer Therapeutics Meeting, October 6–8benzinga · 10/6/2026
- Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer CenterYahoo · 10/6/2026
- Ernexa Therapeutic To Present New Preclinical Data From Its ERNA-101 Lead Oncology Program At The Next-Generation Cancer Therapeutics Meeting, October 6–8Benzinga · 10/6/2026
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga · 10/6/2026
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga · 10/2/2026
- Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the ClinicYahoo · 10/1/2026
- Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 INDYahoo · 9/30/2026
- Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion CytokineBenzinga · 9/30/2026
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga · 9/30/2026
Insider Activity
Insider Actions →- Ratner Elena · August 31, 2026 · Grant5.9K
- Cicala Peter · August 31, 2026 · Grant5.1K
- Cicala Peter · August 31, 2026 · Grant5.9K
- Luther Sanjeev · August 31, 2026 · Grant118.8K
- Wexler William A. · August 31, 2026 · Grant5.9K
- David Polinsky · August 31, 2026 · Grant5.1K
- Bristol James Arthur · August 31, 2026 · Grant5.1K
- Bristol James Arthur · August 31, 2026 · Grant8.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Ernexa Therapeutics reports safety data and new oncology leadership
Ernexa announced that Dr. Robert J. Spiegel has joined the company as a senior executive, strengthening its oncology focus. The company also released safety data from three IND‑enabling studies of its lead iMSC therapy ERNA‑101, showing encouraging results that move the program toward a planned IND filing in Q4 2026. ERNA‑101 was selected for the Emerging Track at the 2026 Cell & Gene Meeting, highlighting its visibility in the cell‑therapy field.
Ernexa Therapeutics reports safety data and new oncology leadership. Ernexa announced that Dr. Robert J. Spiegel has joined the company as a senior executive, strengthening its oncology focus. The company also released safety data from three IND‑enabling studies of its lead iMSC therapy ERNA‑101, showing encouraging results that move the program toward a planned IND filing in Q4 2026. ERNA‑101 was selected for the Emerging Track at the 2026 Cell & Gene Meeting, highlighting its visibility in the cell‑therapy field.